Sign in

    Tim Chiang

    Managing Director and Senior Equity Research Analyst at Northland Securities, Inc.

    Tim Chiang is a Managing Director and Senior Equity Research Analyst at Northland Securities, Inc., specializing in the pharmaceutical and biotechnology sectors. He covers a variety of prominent healthcare companies, with a career performance that includes delivering high-conviction recommendations and a significant history of price target achievement, notably with standout calls on Sarepta Therapeutics. Chiang joined Northland Securities as a Managing Director in March 2020 following previous senior research roles at firms such as Capital One Securities, bringing deep industry expertise and a track record in equity research. He holds professional credentials consistent with senior analyst positions at registered broker-dealers, including FINRA registration and relevant securities licenses.

    Tim Chiang's questions to IDEAYA Biosciences (IDYA) leadership

    Tim Chiang's questions to IDEAYA Biosciences (IDYA) leadership • Q1 2022

    Question

    Tim Chiang asked if establishing an MTD is a requirement for the GSK opt-in and requested more details on the expanded collaboration with Pfizer for darovasertib.

    Answer

    CEO & President Yujiro Hata clarified that the opt-in trigger is the selection of an expansion dose, not necessarily the MTD. He then detailed the two new Pfizer agreements: one enabling a potential registrational trial for darovasertib in metastatic uveal melanoma, and a second for exploring the combination with crizotinib in other cMET-driven tumors.

    Ask Fintool Equity Research AI

    Tim Chiang's questions to KALA BIO (KALA) leadership

    Tim Chiang's questions to KALA BIO (KALA) leadership • Q4 2021

    Question

    Tim Chiang from Northland Securities asked when a triggering point might occur for EYSUVIS net sales to begin rising meaningfully. He also questioned the impact of COVID-19 on the launch and inquired about any side effects observed in the KPI-012 trial.

    Answer

    Todd Bazemore, President and COO, stated that he expects meaningful growth in EYSUVIS revenues to begin in the first half of the year, driven by recent and anticipated payer wins. He added that the return to face-to-face sales interactions post-COVID should also be a positive catalyst. Kim Brazzell, Head of R&D and Chief Medical Officer, reported that no significant adverse events were seen in the first KPI-012 trial, with only one patient noting minor irritation, which is not unexpected given the patient population.

    Ask Fintool Equity Research AI